Results 161 to 170 of about 57,421 (309)

Why Uncertainty Matters - Discounting under Intertemporal Risk Aversion and Ambiguity [PDF]

open access: yes
Uncertainty has an almost negligible impact on project value in the economic standard model. I show that a comprehensive evaluation of uncertainty and uncertainty attitude changes this picture fundamentally.
Christian Traeger
core  

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

An Even Sterner Review: Introducing Relative Prices into the Discounting Debate [PDF]

open access: yes
The Stern Review has had a major influence on the policy discussion on climate change. One reason is that the report has raised the estimated cost of unmitigated climate damages by an order of magnitude compared to most earlier estimates, leading to a ...
Sterner, Thomas, Persson, U. Martin
core  

Effects of simulated and real opioid withdrawal on delay discounting for opioids and money in people who use fentanyl daily. [PDF]

open access: yesExp Clin Psychopharmacol
Shellenberg TP   +9 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Endogenous discounting via wealth, Twin-Peaks and the role of technology [PDF]

open access: yes
We endogenize the discount rate via wealth and provide evidence that wealth affects the discount rate negatively. We give a necessary and sufficient condition for endogenous discounting to lead to the Twin-Peaks of economic growth and show that ...
Ingmar Schumacher
core  

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Discounting in developing countries: a pilot experiment in Timor-Leste [PDF]

open access: yes
We conduct laboratory experiments in Timor-Leste designed to test if individual discount rates vary with the time horizon for which the rate is elicited.
Elisabet E. Rutstrom   +4 more
core  

Home - About - Disclaimer - Privacy